Roche and Zealand reason petrelintide could deliver weight loss comparable to glucagon-like peptide 1 (GLP-1) receptor ...

Roche is doubling down on competing for a slice of the rapidly growing GLP-1 pie. The Swiss pharma giant announced a deal worth up to $5.3 billion on Wednesday with Danish drugmaker Zealand Pharma to ...

Roche has entered an exclusive collaboration and licensing agreement with Zealand Pharma under which the parties will ...

Roche has acquired rights to an obesity therapy by Denmark's Zealand Pharma in a collaboration deal worth up to $5.3 billion, ...

Roche Holding said it would pay Danish biotechnology research company Zealand Pharma up to $5.3 billion under an agreement to ...

Swiss pharmaceutical company Roche announced Friday it will open an innovation center in the Harvard University Enterprise Research Campus in Allston that could employ hundreds. The Roche ...

Public sector leaders who have moved out of their jobs since the last election. Barely a week goes by without an announcement of departure by some public sector leader, be it a chief executive or ...

In amongst a clutch of discontinued phase 3 programmes in Roche's fourth-quarter results update was the news that it has stopped a study of AKT inhibitor ipatasertib as a treatment for first-line ...

Roche revealed in its first-quarter results statement that giredestrant missed the mark in the phase 2 acelERA trial in advanced breast cancer, in what appears to be another blow to the emerging ...

This is yet more Labour Party incompetency – all ideology, no delivery. By the time you add the Brian Roche report into the public service to this, surely we have a case that shows not only do ...